Early stage research takes back seat in Hutchmed push for profit

Chinese biotech company Hutchmed (HKEX:13) is evolving its business strategy, targeting a faster path to profitability amid turbulent economic conditions.

Hutchmed has been undertaking what it described as “an in-depth evaluation of the business,” in response to “challenging market conditions currently affecting the global biopharmaceutical sector.”

The outcome is a strategic shift to focus on the most advanced assets from its in-house pipeline, concentrating on those candidates that are deemed most likely to generate revenues in the short term.